Chloroquine and Hydroxychloroquine is an antimalarial, disease-modifying anti-rheumatic drug. In China and France, some studies provided some indications of possible benefits against pneumonia caused by COVID-19 but need confirmation through randomized trials.
There are many trials going on now to test the efficacy of these drugs. Mechanism of action of hydroxychloroquine includes multiple effects including reduced cytokine production, inhibits immune activation and also interferes with lysosomal activity and membrane stability.
Chloroquine was discovered in 1934 by Hans AndersagIt is usually available as a generic medication. Common side effects include muscle problems, loss of appetite, diarrhoea, and skin rash and serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels. It is a member of the drug class 4-aminoquinoline.
During pregnancy, a woman undergoes with multiple interactions with the health care system that increases her chance of getting infected. So therefore, managing pregnant population presents a unique challenge during COVID-19. The physiological changes and partial immune suppression during pregnancy makes pregnant women and new-born babies susceptible to several infections. Post-partum haemorrhage, maternal sepsis, preeclampsia, and premature rupture of membrane are the most common COVID-19-induced adverse events reported among pregnant women.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia